Positive Results Reported From Phase 2 Study of SRP-5051 in DMD
Sarepta Therapeutics has announced positive results from a global study evaluating its investigational treatment SRP-5051 in people with Duchenne muscular dystrophy (DMD)Â who are amenable to exon 51 skipping. Results from part A of the…